U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Morbidity and Mortality Weekly Report (MMWR)

CDC Stacks Public Health Publications

The Morbidity and Mortality Weekly Report (MMWR) series are CDC’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. The MMWR series includes the following publications: MMWR Weekly, MMWR Recommendations and Reports, CDC Surveillance Summaries and MMWR Supplements. These journals are freely available to the public as Diamond Open Access. For more on MMWR, visit https://www.cdc.gov/mmwr/index.html.

(57)
(67)
(184)
(230)
(500)
(673)
(659)
(403)
(489)
(557)
(246)
(325)
(427)
(406)
(97)
(156)
(103)
(110)
(97)
(92)
(119)
(92)
(108)
(96)
(97)
(92)
(79)
(97)
(87)
(91)
(88)
(76)
(74)
(84)
(80)
(69)
(70)
(73)
(68)
(69)
(59)
(67)
(62)
(64)
(62)
(66)
(72)
(55)
(53)
(55)
(60)
(56)
(58)
(54)
(53)
(56)
(55)
(52)
(54)
(53)
(54)
(54)
(53)
(53)
(53)
(53)
(54)
(53)
(53)
(53)
(53)
(54)
(53)
(53)
(51)
0 of 75
(56)
(63)
(187)
(223)
(500)
(663)
(656)
(409)
(483)
(558)
(231)
(311)
(436)
(413)
(91)
(148)
(100)
(104)
(102)
(92)
(120)
(92)
(104)
(97)
(97)
(91)
(80)
(97)
(86)
(90)
(87)
(76)
(75)
(84)
(80)
(69)
(69)
(71)
(69)
(64)
(60)
(68)
(62)
(62)
(62)
(67)
(72)
(56)
(55)
(54)
(59)
(57)
(58)
(54)
(53)
(55)
(55)
(55)
(53)
(53)
(53)
(53)
(54)
(53)
(53)
(53)
(53)
(53)
(54)
(54)
(53)
(53)
(53)
(53)
(54)
0 of 75
(1)
(7)
(33)
(71)
(44)
(137)
(157)
(161)
(151)
(137)
(163)
(169)
(155)
(160)
(161)
(157)
(164)
(165)
(157)
(165)
(157)
(174)
(142)
(156)
(159)
(135)
(156)
(141)
(142)
(141)
(137)
(138)
(142)
(131)
(162)
(144)
(136)
(152)
(152)
(177)
(206)
(197)
(165)
(187)
(179)
(201)
(205)
(202)
(223)
(226)
(232)
(221)
(225)
(252)
(252)
(278)
0 of 56
(2)
(1)
(4)
(431)
(108)
(406)
(13)
(8559)
0 of 8
(16)
(34)
(2)
(6)
(39)
(4)
(1)
(1)
0 of 8
(10)
(18)
(10)
(9)
(11)
(10)
(25)
(11)
(7)
(27)
(21)
(42)
(7)
(58)
(7)
(23)
(13)
(38)
(10)
(10)
(50)
(8)
(1237)
(23)
(1293)
(32)
(71)
(91)
(27)
(16)
(7)
(128)
(70)
(790)
(24)
(198)
(39)
(61)
(38)
(19)
(26)
(20)
(15)
(26)
(9)
(11)
(17)
(10)
(7)
(49)
(11)
(8)
(224)
(17)
(17)
(8)
(181)
(137)
(130)
(33)
(8)
(15)
(13)
(9)
(10)
(13)
(15)
(9)
(15)
(8)
(30)
(18)
(10)
(7)
(18)
(99)
(13)
(12)
(36)
(8)
(18)
(12)
(7)
(13)
(11)
(30)
(10)
(28)
(9)
(9)
(15)
(21)
(8)
(17)
(7)
(8)
(31)
(77)
(60)
(8)
(7)
(14)
(12)
(13)
(15)
(19)
(11)
(85)
(13)
(14)
(31)
(13)
(30)
(14)
(12)
(187)
(7)
(7)
(17)
(8)
(18)
(53)
(11)
(10)
(8)
(24)
(21)
(691)
(8)
(11)
(15)
(59)
(205)
(7)
(9)
(18)
(10)
(66)
(14)
(23)
(7)
(17)
(22)
(21)
(7)
(15)
(10)
(9)
(24)
(13)
(31)
(20)
(7)
(13)
(29)
(13)
(31)
(74)
(26)
(20)
(7)
(7)
(8)
(13)
(28)
(25)
(9)
(941)
(9)
(14)
(14)
(740)
(35)
(103)
(10)
(51)
(10)
(20)
(11)
(11)
(9)
(58)
(12)
(20)
(14)
(49)
(20)
(21)
(19)
(20)
(16)
(177)
(81)
(2981)
(316)
(263)
(12)
(543)
(215)
(37)
(38)
(25)
(14)
(15)
(14)
(12)
(34)
(10)
(80)
(14)
(11)
(8)
(23)
(8)
(8)
(439)
(23)
(15)
(8)
(73)
(19)
(28)
(31)
(24)
(10)
(18)
(18)
(18)
(45)
(74)
(8)
(40)
(11)
(8)
(11)
(20)
(19)
(58)
(9)
(23)
(8)
(16)
(34)
(44)
(83)
(9)
(10)
(9)
(21)
(65)
(13)
(14)
(28)
(25)
(14)
(10)
(10)
(8)
(166)
(26)
(11)
(14)
(35)
(24)
(9)
(9)
(24)
(26)
(12)
(92)
(4171)
(642)
(34)
(12)
(17)
(14)
(11)
(10)
(12)
(13)
(9)
(28)
(16)
(19)
(8)
(12)
(27)
(17)
(46)
(20)
(28)
(36)
(10)
(20)
(21)
(8)
(8)
(8)
(66)
(91)
(9)
(25)
(27)
(13)
(21)
(22)
(8)
(39)
(56)
(69)
(21)
(15)
(149)
(16)
(14)
(8)
(12)
(32)
(19)
(19)
(16)
(22)
(10)
(11)
(144)
(45)
(32)
(9)
(41)
(15)
(32)
(660)
(26)
(9)
(56)
(14)
(130)
(9)
(18)
(62)
(10)
(10)
(30)
(11)
(10)
(13)
(21)
(8)
(15)
(23)
(111)
(23)
(1338)
(15)
(10)
(17)
(11)
(13)
(8)
(8)
(48)
(8)
(42)
(45)
(25)
(47)
(13)
(25)
(186)
(14)
(16)
(11)
(586)
(394)
(15)
(21)
(14)
(152)
(16)
(53)
(9)
(28)
(10)
(19)
(162)
(8)
(10)
(14)
(31)
(9)
(8)
(9)
(19)
(11)
(8)
(8)
(110)
(10)
(78)
(11)
(68)
(60)
(17)
(23)
(60)
(132)
(19)
(105)
(58)
(12)
(39)
(126)
(35)
(97)
(52)
(17)
(10)
(11)
(12)
(12)
(8)
(14)
(52)
(71)
(116)
(173)
(25)
(17)
(50)
(13)
(10)
(33)
(12)
(10)
(46)
(8)
(29)
(11)
(8)
(8)
(60)
(31)
(90)
(44)
(12)
(28)
(51)
(9)
(207)
(18)
(32)
(17)
(19)
(2446)
(16)
(19)
(18)
(11)
(106)
(8)
(207)
(232)
(20)
(38)
(23)
(8)
(8)
(9)
(18)
(240)
(11)
(49)
(678)
(47)
(10)
(308)
(15)
(63)
(23)
(17)
(8)
(21)
(188)
(54)
(48)
(8)
(45)
(114)
(50)
(125)
(28)
(11)
(10)
(596)
(15)
(22)
(13)
(61)
(9)
(26)
(29)
(14)
(37)
(12)
(8)
(32)
(12)
(22)
(8)
(8)
(22)
(13)
(16)
(11)
(10)
(73)
(9)
(10)
(10)
(74)
(32)
(114)
(9)
(13)
(41)
(17)
(55)
(17)
(13)
(16)
(18)
(10)
(17)
(44)
(66)
(10)
(11)
(9)
(10)
(12)
(177)
(12)
(14)
(17)
(1181)
(9)
(9)
(8)
(50)
(10)
(44)
(109)
(10)
(16)
(8)
(19)
(312)
(33)
(23)
(12)
(9)
(84)
(11)
(12)
(41)
(11)
(18)
(20)
(8)
(11)
(8)
(8)
(19)
(58)
(32)
(82)
(14)
(37)
(8)
(21)
(40)
(13)
(17)
(17)
(9)
(9)
(66)
(19)
(963)
(103)
(15)
(48)
(30)
(8)
(11)
(57)
(3831)
(11)
(9)
(9)
(29)
(8)
(22)
(16)
(16)
(15)
(17)
(10)
(8)
(13)
(8)
(11)
(18)
(9)
(14)
(15)
(9)
(16)
(41)
(43)
(20)
(10)
(27)
(11)
(12)
(10)
(15)
(243)
(18)
(22)
(36)
(8)
(15)
(113)
(10)
(257)
(611)
(72)
(11)
(23)
(17)
(8)
(11)
(15)
(9)
(10)
(10)
(301)
(12)
(11)
(8)
(14)
(12)
(11)
(20)
(10)
(10)
(16)
(13)
(13)
(22)
(10)
(10)
(65)
(10)
(9)
(10)
(9)
(19)
(12)
(9)
(144)
(18)
(15)
(8)
(33)
(144)
(22)
(11)
(171)
(10)
(8)
(8)
(70)
(30)
(25)
(21)
(343)
(24)
(115)
(36)
(11)
(8)
(84)
(34)
(14)
(8)
(10)
(21)
(29)
(20)
(16)
(1141)
(18)
(27)
(18)
(22)
(110)
(15)
(22)
(23)
(349)
(19)
(72)
(16)
(26)
(14)
(15)
(10)
(26)
(35)
(10)
(9)
(11)
(216)
(50)
(16)
(23)
(34)
(21)
(10)
(19)
(74)
(20)
(9)
(233)
(1005)
(22)
(24)
(71)
(101)
(2519)
(11)
(104)
(12)
(23)
(15)
(16)
(14)
(93)
(177)
(38)
(14)
(11)
(279)
(15)
(9)
(13)
(45)
(8)
(32)
(91)
(9)
(17)
(18)
(11)
(23)
(71)
(37)
(18)
(12)
(8)
(12)
(21)
(10)
(28)
(10)
(10)
(8)
(24)
(104)
(187)
(28)
(29)
(25)
(10)
(20)
(9)
(58)
(195)
(303)
(67)
(8)
(21)
(12)
(8)
(59)
(18)
(34)
(9)
(38)
(177)
(10)
(617)
(31)
(32)
(146)
(241)
(12)
(18)
(10)
(8)
(122)
(11)
(126)
(9)
(16)
(18)
(15)
(20)
(11)
(9)
(19)
(11)
(28)
(35)
(37)
(11)
(8)
(65)
(22)
(42)
(14)
(16)
(28)
(10)
(10)
(14)
(12)
(80)
(31)
(8)
(39)
(9)
(20)
(18)
(12)
(184)
(28)
(9)
(23)
(71)
(25)
(23)
(25)
(14)
(8)
(9)
(108)
(8)
(22)
(16)
(44)
(16)
(134)
(51)
(10)
(19)
(10)
(56)
(10)
(8)
(12)
(18)
(94)
(31)
(35)
(12)
(49)
(8)
(38)
(91)
(9)
(22)
(14)
(183)
(8)
(11)
(8)
(19)
(33)
(21)
(19)
(12)
(8)
(69)
(9)
(54)
(15)
(12)
(8)
(15)
(8)
(8)
(10)
(58)
(19)
(182)
(28)
(36)
(22)
(106)
(19)
(157)
(9)
(12)
(15)
(13)
(68)
(9)
(14)
(182)
(10)
(10)
(19)
(62)
(13)
(29)
(17)
(50)
(17)
(19)
(9)
(14)
(466)
(48)
(50)
(105)
(11)
(17)
(104)
(8)
(29)
(24)
(34)
(21)
(40)
(10)
(23)
(31)
(20)
(35)
(21)
(18)
(12)
(8)
(43)
(94)
(22)
(26)
(9)
(23)
(9)
(12)
(8)
(39)
(14)
(14)
(59)
(11)
(9)
(38)
(17)
(16)
(39)
(16)
(78)
(8)
(43)
(13)
(15)
(10)
(46)
(27)
(762)
(30)
(57)
(10)
(12)
(29)
(33)
(10)
(10)
(8)
(14)
(51)
(8)
(61)
(16)
(9)
0 of 1000
(12)
(12)
(15)
(7)
(23)
(9)
(7)
(18)
(8)
(7)
(10)
(11)
(7)
(9)
(7)
(10)
(9)
(11)
(11)
(19)
(9)
(11)
(9)
(10)
(27)
(8)
(9)
(12)
(23)
(15)
(9)
(7)
(7)
(7)
(9)
(13)
(11)
(9)
(15)
(7)
(7)
(7)
(7)
(9)
(8)
(19)
(9)
(9)
(7)
(7)
(13)
(7)
(7)
(9)
(7)
(9)
(7)
(16)
(13)
(7)
(12)
(12)
(22)
(28)
(15)
(8)
(8)
(13)
(7)
(19)
(12)
(12)
(13)
(15)
(16)
(9)
(10)
(7)
(11)
(28)
(7)
(13)
(28)
(7)
(10)
(11)
(11)
(13)
(10)
(8)
(18)
(9)
(10)
(16)
(29)
(8)
(12)
(12)
(13)
(8)
(9)
(7)
(28)
(9)
(16)
(7)
(29)
(7)
(8)
(8)
(11)
(16)
(16)
(12)
(35)
(8)
(11)
(16)
(18)
(9)
(29)
(9)
(14)
(22)
(31)
(11)
(7)
(7)
(10)
(7)
(18)
(9)
(7)
(9)
(7)
(7)
(7)
(11)
(9)
(23)
(20)
(10)
(7)
(7)
(15)
(10)
(8)
(37)
(8)
(22)
(10)
(16)
(11)
(10)
(24)
(13)
(7)
(11)
(7)
(9)
(11)
(9)
(12)
(21)
(9)
(9)
(7)
(11)
(7)
(16)
(9)
(7)
(9)
(12)
(19)
(13)
(7)
(7)
(7)
(11)
(10)
(7)
(9)
(24)
(7)
(8)
(10)
(12)
(8)
(13)
(25)
(23)
(7)
(24)
(16)
(9)
(7)
(10)
(9)
(8)
(8)
(13)
(9)
(9)
(10)
(7)
(10)
(7)
(20)
(8)
(9)
(7)
(18)
(17)
(11)
(10)
(12)
(9)
(12)
(7)
(9)
(7)
(9)
(18)
(8)
(12)
(8)
(8)
(8)
(13)
(7)
(7)
(8)
(15)
(7)
(17)
(17)
(16)
(8)
(20)
(7)
(8)
(11)
(11)
(21)
(8)
(11)
(10)
(13)
(9)
(8)
(7)
(12)
(8)
(15)
(9)
(11)
(7)
(15)
(12)
(17)
(16)
(7)
(18)
(24)
(11)
(7)
(7)
(12)
(8)
(19)
(20)
(16)
(11)
(12)
(7)
(8)
(10)
(14)
(16)
(7)
(9)
(11)
(20)
(15)
(9)
(16)
(48)
(9)
(11)
(24)
(11)
(8)
(9)
(7)
(10)
(9)
(7)
(10)
(8)
(53)
(13)
(9)
(11)
(15)
(42)
(16)
(8)
(8)
(29)
(10)
(7)
(10)
(8)
(8)
(24)
(8)
(11)
(12)
(8)
(13)
(21)
(24)
(10)
(10)
(16)
(20)
(11)
(10)
(15)
(17)
(12)
(18)
(7)
(17)
(16)
(10)
(15)
(18)
(14)
(16)
(22)
(7)
(9)
(17)
(12)
(15)
(8)
(18)
(20)
(15)
(11)
(29)
(7)
(10)
(23)
(7)
(7)
(27)
(8)
(7)
(26)
(18)
(8)
(12)
(11)
(8)
(36)
(15)
(12)
(7)
(8)
(15)
(16)
(7)
(7)
(9)
(10)
(9)
(17)
(7)
(12)
(12)
(13)
(12)
(16)
(9)
(13)
(8)
(15)
(24)
(8)
(8)
(8)
(7)
(17)
(9)
(7)
(28)
(12)
(15)
(13)
(9)
(7)
(7)
(9)
(8)
(7)
(8)
(14)
(9)
(14)
(17)
(7)
(8)
(7)
(10)
(11)
(7)
(16)
(9)
(59)
(12)
(8)
(8)
(7)
(7)
(9)
(7)
(18)
(7)
(8)
(18)
(9)
(15)
(10)
(8)
(25)
(11)
(8)
(9)
(14)
(26)
(23)
(8)
(43)
(11)
(14)
(7)
(15)
(11)
(20)
(7)
(28)
(15)
(10)
(9)
(26)
(18)
(7)
(8)
(8)
(7)
(18)
(15)
(15)
(11)
(7)
(8)
(7)
(10)
(14)
(8)
(30)
(15)
(7)
(9)
(19)
(18)
(15)
(9)
(7)
(7)
(8)
(13)
(11)
(15)
(17)
(8)
(49)
(7)
(32)
(13)
(10)
(16)
(7)
(23)
(24)
(9)
(10)
(25)
(8)
(20)
(7)
(7)
(13)
(7)
(11)
(9)
(7)
(7)
(10)
(9)
(8)
(9)
(7)
(7)
(10)
(16)
(14)
(12)
(7)
(10)
(7)
(20)
(9)
(15)
(7)
(11)
(12)
(11)
(13)
(8)
(7)
(19)
(26)
(17)
(7)
(15)
(9)
(8)
(18)
(17)
(8)
(8)
(12)
(7)
(10)
(7)
(9)
(8)
(18)
(18)
(11)
(8)
(35)
(21)
(7)
(7)
(18)
(9)
(7)
(10)
(7)
(10)
(9)
(14)
(14)
(10)
(24)
(12)
(8)
(53)
(7)
(7)
(19)
(8)
(10)
(7)
(10)
(8)
(11)
(7)
(9)
(8)
(8)
(20)
(13)
(27)
(8)
(8)
(19)
(7)
(19)
(7)
(11)
(7)
(12)
(7)
(11)
(11)
(28)
(10)
(9)
(7)
(20)
(10)
(13)
(7)
(8)
(9)
(13)
(11)
(10)
(7)
(13)
(9)
(7)
(10)
(8)
(7)
(7)
(10)
(14)
(9)
(38)
(23)
(10)
(8)
(7)
(10)
(11)
(10)
(13)
(15)
(10)
(7)
(17)
(10)
(7)
(7)
(11)
(11)
(12)
(8)
(10)
(18)
(14)
(8)
(10)
(21)
(16)
(14)
(14)
(9)
(15)
(9)
(19)
(24)
(11)
(20)
(21)
(16)
(7)
(7)
(10)
(23)
(7)
(8)
(17)
(7)
(9)
(10)
(7)
(7)
(17)
(8)
(8)
(7)
(9)
(9)
(13)
(10)
(8)
(13)
(9)
(13)
(8)
(18)
(7)
(7)
(27)
(12)
(8)
(15)
(9)
(17)
(8)
(18)
(7)
(26)
(12)
(9)
(9)
(19)
(10)
(7)
(7)
(13)
(7)
(7)
(8)
(10)
(21)
(15)
(35)
(14)
(18)
(7)
(7)
(7)
(8)
(21)
(16)
(24)
(24)
(18)
(8)
(7)
(18)
(12)
(7)
(7)
(13)
(25)
(7)
(8)
(12)
(11)
(19)
(7)
(27)
(18)
(10)
(10)
(8)
(12)
(7)
(7)
(7)
(10)
(7)
(7)
(10)
(16)
(12)
(10)
(7)
(18)
(7)
(25)
(10)
(15)
(10)
(18)
(24)
(13)
(16)
(9)
(19)
(13)
(26)
(16)
(18)
(8)
(10)
(8)
(10)
(14)
(7)
(10)
(7)
(13)
(7)
(7)
(11)
(17)
(7)
(15)
(13)
(13)
(13)
(8)
(33)
(8)
(11)
(11)
(8)
(11)
(12)
(21)
(10)
(9)
(12)
(23)
(8)
(11)
(14)
(8)
(19)
(11)
(8)
(8)
(11)
(9)
(8)
(11)
(10)
(8)
(8)
(14)
(13)
(10)
(16)
(9)
(30)
(11)
(11)
(10)
(14)
(23)
(8)
(9)
(12)
(11)
(10)
(8)
(8)
(9)
(20)
(17)
(12)
(10)
(8)
(18)
(13)
(17)
(11)
(9)
(29)
(10)
(9)
(13)
(11)
(8)
(29)
(13)
(13)
(9)
(11)
(40)
(8)
(10)
(12)
(14)
(8)
(13)
(16)
(9)
(12)
(8)
(9)
(11)
(8)
(9)
(40)
(10)
(9)
(20)
(17)
(8)
(24)
(13)
(10)
(24)
(9)
(18)
(20)
(9)
(9)
(8)
(8)
(29)
(15)
(8)
(73)
(9)
(38)
(8)
(23)
(10)
(24)
(9)
(12)
(9)
(8)
(10)
(12)
(11)
(8)
(22)
(9)
(13)
(10)
(16)
(8)
(9)
(13)
(17)
(11)
(8)
(12)
(15)
(9)
(9)
(13)
(9)
(8)
(20)
(14)
(33)
(9)
(16)
(10)
(10)
(10)
(12)
(8)
(9)
(33)
(16)
(8)
(10)
(8)
(11)
(13)
(14)
(21)
(10)
(15)
(8)
(8)
(12)
(8)
(15)
(12)
(18)
(9)
(12)
(13)
(13)
(23)
(11)
(15)
(12)
(9)
(8)
(8)
(13)
(25)
(13)
(17)
(8)
(13)
(11)
(13)
(11)
(9)
(10)
(8)
(10)
(21)
(13)
(21)
(23)
(25)
(8)
(9)
(11)
(11)
(15)
(10)
(13)
(10)
(9)
(19)
(14)
(10)
(15)
(28)
0 of 1000
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(5)
(4)
(1)
(1)
(1)
(1)
(3)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(2)
(1)
(9)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(3)
(1)
(3)
(1)
(2)
(1)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(7)
(3)
(2)
(3)
(1)
(1)
(1)
(1)
(9)
(1)
(3)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(16)
(1)
(1)
(14)
(7)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(33)
(1)
(2)
(106)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(13)
(1)
(1)
(1)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(6)
(1)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(13)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(8)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(3)
(1)
(1)
(2)
(68)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(8)
(1)
(4)
(3)
(5)
(6)
(2)
(1)
(11)
(1)
(2)
(3)
(1)
(4)
(7)
(1)
(1)
(1)
(1)
(6)
(3)
(1)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(12)
(1)
(3)
(1)
(3)
(1)
(1)
(125)
(1)
(2)
(1)
(1)
(4)
(22)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3943)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(2)
(3)
(1)
(3)
(1)
(1)
(1)
(2)
(11)
(10)
(1)
(1)
(41)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(14)
(1)
(1)
(4)
(20)
(1)
(7)
(3)
(1)
(1)
(1)
(3)
(1)
(1)
(5)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(13)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(7)
(2)
(1)
(1)
(2)
(1)
(65)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(6)
(5)
(1)
(1)
(1)
(10)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(33)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(3)
(21)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(3)
(425)
(1)
(1)
(1)
(2)
(1)
(1)
(5)
(1)
(3)
(1)
(1)
(6)
(1)
(6)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(3)
(5)
(2)
(2)
(2)
(4)
(3)
(3)
(4)
(2)
(2)
(2)
(3)
(3)
(9)
(2)
(2)
(2)
(2)
(2)
(9)
(7)
(4)
(2)
(2)
(5)
(2)
(12)
(2)
(7)
(12)
(4)
(2)
(3)
(4)
(2)
(3)
(4)
(2)
(5)
(4)
(7)
(2)
(5)
(7)
(2)
(9)
(4)
(2)
(4)
(9)
(2)
(2)
(2)
(2)
(4)
(2)
(8)
(9)
(3)
(3)
(2)
(2)
(5)
(2)
(5)
(4)
(3)
(2)
(9)
(4)
(4)
(3)
(6)
(4)
(2)
(3)
(2)
(6)
(2)
(2)
(11)
(3)
(2)
(2)
(2)
(3)
(2)
(10)
(2)
(4)
(8)
(2)
(15)
(2)
(2)
(3)
(20)
(6)
(2)
(2)
(5)
(2)
(13)
(11)
(2)
(24)
(2)
(3)
(3)
(7)
(2)
(3)
(3)
(3)
(2)
(9)
(2)
(14)
(2)
(7)
(3)
(4)
(3)
(2)
(3)
(9)
(5)
(9)
(50)
(8)
(3)
(13)
(3)
(3)
(2)
(4)
(3)
(9)
(5)
(2)
(2)
(3)
(2)
(15)
(9)
(5)
(4)
(2)
(5)
(4)
(5)
(4)
(5)
(5)
(11)
(4)
(12)
(5)
(2)
(2)
(7)
(5)
(3)
(3)
(2)
(5)
(2)
(2)
(2)
(3)
(2)
(3)
(2)
(7)
(2)
(2)
(3)
(3)
(3)
(6)
(2)
(3)
(3)
(10)
(2)
(16)
(2)
(7)
(9)
(6)
(4)
(7)
(5)
(4)
(11)
(3)
(4)
(13)
(17)
(2)
(2)
(149)
(24)
(2)
(2)
(4)
(8)
(7)
(11)
(8)
(5)
(3)
(13)
(4)
(17)
(6)
(9)
(2)
(22)
(2)
(2)
(6)
(3)
(9)
(4)
(2)
(3)
(15)
(3)
(4)
(3)
(6)
(8)
(15)
(2)
(23)
(2)
(2)
(4)
(5)
(5)
(24)
(2)
(4)
(2)
(7)
(2)
(2)
(9)
(3)
(2)
(9)
(6)
(11)
(5)
(15)
(4)
(2)
(3)
(5)
(6)
(2)
(118)
(5)
(18)
(3)
(2)
(7)
(125)
(2)
(3)
(2)
(5)
(7)
(2)
(3)
(2)
(4)
(6)
(3)
(3)
(2)
(3)
(2)
(6)
(10)
(12)
(2)
(3)
(3)
(4)
(4)
(9)
(2)
(2)
(2)
(5)
(6)
(4)
(2)
(2)
(2)
(2)
(2)
(4)
(13)
(4)
(2)
(3)
(2)
(9)
(4)
(2)
(2)
(2)
(7)
(2)
(2)
(2)
(2)
(2)
(3)
(2)
(4)
(3)
(3)
(3)
(4)
(2)
(12)
(4)
(2)
(5)
(6)
(5)
(2)
(3)
(14)
(4)
(2)
(2)
(2)
(2)
(14)
(7)
(2)
(2)
(3)
(3)
(2)
(2)
(7)
(44)
(183)
(2)
(88)
(115)
(2)
(8)
(2)
(3)
(26)
(80)
(2)
(2)
(22)
(3)
(2)
(36)
(30)
(10)
(8)
(16)
(10)
(5)
(2)
(14)
(180)
(2)
(3)
(3)
(2)
(93)
(6)
(2)
(2)
(4)
(317)
(7)
(11)
(2)
(6)
(4)
(3)
(3)
(6)
(2)
(4)
(4)
(2)
(3)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(2)
(2)
(4)
(2)
(2)
(4)
(2)
(3)
(2)
(2)
(2)
(2)
(3)
(2)
(5)
(4)
(2)
(2)
(2)
(2)
(4)
(4)
(2)
(3)
(15)
(3)
(2)
(2)
(14)
(2)
(5)
(2)
(6)
(15)
(13)
(4)
(2)
(3)
(5)
(2)
(8)
(2)
(4)
(2)
(2)
(3)
(3)
(7)
(4)
(2)
(2)
(4)
(2)
(2)
(4)
(2)
(2)
(2)
0 of 1000
(2)
(1)
(111)
(8)
(1)
(2855)
(2004)
(4)
(13)
(34)
(81)
(3)
(1)
(1)
(2)
(3)
(19)
(1)
(46)
(4166)
(2)
(4)
(2)
0 of 23
(1)
(15)
(33)
(8)
(13)
(1)
(8)
(2)
(2)
(4)
(5)
(25)
(1)
(2)
(180)
(1)
(114)
(2)
(3)
(7)
(1)
(3)
(10)
(11)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(14)
(168)
(159)
(1)
(1)
(1)
(1)
(20)
(1)
(28)
(1)
(1)
(2)
(1)
(23)
(2)
(1)
(1)
(1)
(1)
(23)
(8)
(1)
(2)
(3)
(1)
(6)
(1)
(19)
(1)
(7)
(2)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(3)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(12)
(1)
(1)
(1)
(2)
(1)
(1)
(16)
(1)
(3)
(1)
(20)
(1)
(5)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(4)
(1)
(2)
(2)
(2)
(1)
(871)
(2)
(1)
(11)
(1)
(3)
(6)
(1)
(1)
(1)
(87)
(4)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(3)
(2)
(1)
(14)
(3)
(4)
(53)
(1)
(1)
(1)
(1)
(8)
(17)
(1)
(1)
(1)
(1)
(7)
(1)
(8)
(266)
(1)
(7)
(1)
(1)
(3)
(201)
(2)
(2)
(1)
(1)
(4)
(1)
(1)
(1)
(10)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(2)
(2)
(39)
(1)
(1)
(17)
(13)
(1)
(5)
(1)
(2)
(11)
(1)
(1)
(177)
(2)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(4)
(1)
(7)
(1)
(4)
(1)
(1)
(68)
(1)
(1)
(1)
(1)
(1)
(1)
(12)
(39)
(2)
(1)
(1)
(5)
(3)
(12)
(316)
(1)
(1)
(1)
(1)
(28)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(468)
(3)
(6)
(42)
(1)
(3)
(12)
(5)
(4)
(10)
(1)
(1)
(20)
(1)
(8)
(1)
(1)
(1)
(3)
(2)
(15)
(14)
(8)
(2)
(18)
(1)
(112)
(1)
(1)
(1)
(1)
(4)
(5)
(24)
(1)
(1)
(9)
(1)
(3)
(76)
(307)
(1)
(1)
(1)
(31)
(161)
(12)
(1)
(174)
(3)
(3)
(10)
(7)
(25)
(1)
(1)
(1)
(4)
(23)
(42)
(1)
(1)
(1)
(1)
(111)
(1)
(1)
(1)
(1)
(213)
(18)
(1)
(1)
(9)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(7)
(4)
(1)
(1)
(1)
(1)
(4)
(32)
(1)
(1)
(1)
(1)
(2)
(3)
(1)
(13)
(3)
(1)
(4)
(5)
(96)
(1)
(2)
(209)
(1)
(3)
(2)
(2)
(3)
(1)
(1)
(127)
(9)
(7)
(3)
(2)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(204)
(1)
(1)
(272)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(55)
(1)
(1)
(1)
(1)
(1)
(5)
(265)
(12)
(5)
(3)
(11)
(1)
(8)
(1)
(3)
(1)
(1)
(3)
(1)
(306)
(1)
(131)
(1)
(163)
(1)
(1)
(1)
(77)
(4)
(3)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(2)
(1)
(3)
(1)
(2)
(3)
(3)
(112)
(1)
(1)
(9)
(2)
(27)
(34)
(1)
(1)
(3)
(18)
(60)
(1)
(237)
(2)
(1)
(187)
(2)
(1)
(5)
(1)
(500)
(6)
(1)
(7)
(1)
(1)
(156)
(5)
(1)
(16)
(2)
(1)
(6)
(3)
(2)
(1)
(1)
(3)
(3)
(5)
(9)
(4)
(31)
(1)
(1)
(4)
(1)
(248)
(45)
(4)
(1)
(1)
(2)
(1)
(10)
(8)
(5)
(2)
(1)
(1)
(1)
(57)
(72)
(80)
(241)
(256)
(318)
(52)
(45)
(51)
(88)
(1)
(1)
(1)
(1)
(1)
(558)
(114)
(1)
(1)
(4)
(10)
(1)
(1)
(267)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(7)
(8)
(31)
(8)
(7)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(301)
(1)
(1)
(13)
(10)
(2)
(1)
(27)
(1)
(1)
(1)
(1)
(18)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(19)
(1)
(1)
(1)
(5)
(16)
(1)
(2)
(1)
(154)
(1)
(1)
(1)
(5)
(1)
(9)
(1)
(1)
(3)
(2)
(1)
(90)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(5)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(11)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(3)
(3)
(1)
(4)
(1)
(4)
(1)
(1)
(1)
(8)
(1)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(18)
(13)
(1)
(14)
(1)
(1)
(13)
(11)
(1)
(2)
(1)
(117)
(46)
(4)
(8)
(2)
(1)
(9)
(4)
(20)
(1)
(2)
(2)
(1)
(5)
(2)
(1)
(2)
(1)
(14)
(1)
(1)
(1)
(1)
(2)
(2)
(22)
(24)
(1)
(1)
(1)
(3)
(1)
(18)
(1)
(1)
(10)
(1)
(1)
(1)
(1)
(1)
(185)
(1)
(1)
(481)
(22)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(11)
(8)
(1)
(1)
(1)
(7)
(1)
(1)
(130)
(1)
(11)
(27)
(1)
(1)
(1)
(67)
(7028)
(1)
(11)
(1)
(5)
(154)
(1)
(1)
(11)
(79)
(1)
(1)
(3)
(3)
(31)
(1)
(4)
(2)
(4)
(215)
(1)
(1)
(30)
(2)
(1)
(390)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(256)
(1)
(1)
(3)
(1)
(1)
(195)
(1)
(1)
(2)
(1)
(45)
(1)
(3)
(9)
(6)
(8)
(9)
(1)
(2)
(1)
0 of 775
(1)
(55)
(9)
(1)
(2)
(25)
(295)
(2)
(2)
(2)
(3)
(1)
(5)
(27)
(1)
(3)
(5)
(14)
(60)
(10)
(1)
(2)
(4)
(1)
(787)
(2802)
(3)
(5)
(5)
(37)
(1)
(16)
(1)
(7)
(3)
(16)
(3)
(27)
(1)
(108)
(2)
(383)
(51)
(1)
(1)
(1)
(1)
(2004)
(1)
(4)
(1)
(8)
(344)
(4)
(3)
(48)
(3)
0 of 57
(3)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(8)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(2)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(3)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
0 of 794
(82)
(4)
(1)
(6)
0 of 4
Showing 981 - 1000 of 9550 results
  • Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARSCoV2 High Transmission Periods United States December 2020January 2022
    Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022
    Iuliano, A. Danielle ;
    Brunkard, Joan M.
    2022/01/28 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? The SARS-CoV-2 B.1.1.529 (Omicron) variant became predominant in the United States by late December 2021, leading to a surge in COVID-19 cases and associated ED visits and hospitalizations. What is added by this report? Despite Omicron seeing the highest reported numbers of COVID-19 cases and hospitalizations ...
    Supporting Files Public Domain
  • Erratum Vol 71 No 1
    Erratum: Vol. 71, No. 1
    1 28 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    cdc:113672In the report “Alcohol Consumption and Binge Drinking During Pregnancy Among Adults Aged 18–49 Years — United States, 2018–2020,” in the figure on page 12, for Region 8, the values listed should have been 10.8% (7.3%–14.3%). [MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):10-13.]
    Supporting Files Public Domain
  • Erratum Vol 71 No 2
    Erratum: Vol. 71, No. 2
    1 28 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    cdc:114301This corrects the article "Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥20 Years — United States, 1999–2018" on page 43 [MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):43-47.]In the report “Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥20 Years — United States, 1999–2018 ...
    Supporting Files Public Domain
  • Use of 15Valent Pneumococcal Conjugate Vaccine and 20Valent Pneumococcal Conjugate Vaccine Among US Adults Updated Recommendations of the Advisory Committee on Immunization Practices United States 2022
    Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
    Kobayashi, Miwako ;
    Farrar, Jennifer L.
    01/28/2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 and PCV15 with those to 13-valent PCV ( ...
    Supporting Files Public Domain
  • Effectiveness of a Third Dose of PfizerBioNTech and Moderna Vaccines in Preventing COVID19 Hospitalization Among Immunocompetent and Immunocompromised Adults United States AugustDecember 2021
    Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
    Tenforde, Mark W. ;
    Patel, Manish M.
    1 28 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, and are highly effective against COVID-19-associated hospitalization among eligible persons who receive 2 doses (1,2). However, vaccine effectiveness (VE) among persons with immunocompromi ...
    Supporting Files Public Domain
  • Surveillance for Violent Deaths National Violent Death Reporting System 39 States the District of Columbia and Puerto Rico 2018 Supplementary Tables
    Surveillance for Violent Deaths — National Violent Death Reporting System, 39 States, the District of Columbia, and Puerto Rico, 2018: Supplementary Tables
    Petrosky, Emiko ;
    Ertl, Allison
    01/28/2022 | Surveillance Summaries: Morbidity and Mortality Weekly Report (MMWR)
    Table S1. Number, Percentage, and Rate of Deaths, by Incident Type and Manner of Death – National Violent Death Reporting System, 39 States and District of Columbia, 2018Table S2. Number, Percentage, and Rate of Deaths, by Incident Type and Manner of Death – National Violent Death Reporting System, 39 States (California Statewide) and District of C ...
    Supporting Files Public Domain
  • Notes From the Field Increased Incidence of FentanylRelated Deaths Involving Parafluorofentanyl or Metonitazene Knox County Tennessee November 2020August 2021
    Notes From the Field: Increased Incidence of Fentanyl-Related Deaths Involving Para-fluorofentanyl or Metonitazene — Knox County, Tennessee, November 2020–August 2021
    Trecki, Jordan ;
    Gerona, Roy R.
    1 28 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    No Description
    Supporting Files Public Domain
  • COVID19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence 25 US Jurisdictions April 4December 25 2021
    COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021
    Johnson, Amelia G. ;
    Amin, Avnika B.
    2022/01/28 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Previous reports of COVID-19 case, hospitalization, and death rates by vaccination status| indicate that vaccine protection against infection, as well as serious COVID-19 illness for some groups, declined with the emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, and waning of vaccine-induced immunity (1-4). ...
    Supporting Files Public Domain
  • Trends in Disease Severity and Health Care Utilization During the Early Omicron Variants Period Compared with Previous SARSCoV2 High Transmission Periods US December 2020January 2022
    Trends in Disease Severity and Health Care Utilization During the Early Omicron Variants Period Compared with Previous SARS-CoV-2 High Transmission Periods — U.S. December 2020–January 2022
    Iuliano, A. Danielle ;
    Brunkard, Joan M.
    January 25, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? The SARS-CoV-2 B.1.1.529 (Omicron) Variants became predominant in the U.S. by late December 2021, leading to a surge in COVID-19 cases and associated ED visits and hospitalizations.What is added by this report? Despite Omicron seeing the highest reported numbers of COVID-19 cases and hospitalizations during t ...
    Supporting Files Public Domain
  • Supplementary Figure Ratio of Emergency Department Visits New Hospital Admissions and Deaths to 1000 COVID19 Cases by COVID19 High Transmission Period United States December 1 2020January 15 2022
    Supplementary Figure. Ratio of Emergency Department Visits, New Hospital Admissions, and Deaths to 1,000 COVID-19 Cases, by COVID-19 High Transmission Period, — United States, December 1, 2020–January 15, 2022
    Charts, Diagrams, Etc.
    January 25, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Supplementary figure for: Trends in Transmission and disease severity comparing Omicron Variants emergence with previous SARS-CoV-2 high Transmission periods, United States, December 2020-January 2022.
    Supporting Files Public Domain
  • Disease Surveillance Among USBound Immigrants and Refugees Electronic Disease Notification System United States 20142019 Supplementary Figures
    Disease Surveillance Among U.S.-Bound Immigrants and Refugees — Electronic Disease Notification System, United States, 2014–2019 [Supplementary Figures]
    Centers for Disease Control and Prevention (U.S.)
    01/21/2022 | Surveillance Summaries: Morbidity and Mortality Weekly Report (MMWR)
    Supplementary Figure 1. Top ten countries of nationality for new-arrival immigrants by year of arrival, 2014-2019Supplementary Figure 2. Countries of nationality for refugees and eligible others by year of arrival, 2014-2019
    Public Domain
  • Progress Toward Poliomyelitis Eradication Afghanistan January 2020November 2021
    Progress Toward Poliomyelitis Eradication ― Afghanistan, January 2020–November 2021
    Sadigh, Katrin S. ;
    Akbar, Irfan Elahi
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Wild polioVirus types 2 and 3 were declared eradicated in 2015 and 2019, respectively, and, since 2017, Transmission of wild polioVirus type 1 (WPV1) has been detected only in Afghanistan and Pakistan. In 2020, these countries reported their highest number of WPV1 cases since 2014 and experienced outbreaks of type 2 circulating vaccine-derived poli ...
    Supporting Files Public Domain
  • ZikaAssociated Birth Defects Reported in Pregnancies with Laboratory Evidence of Confirmed or Possible Zika Virus Infection US Zika Pregnancy and Infant Registry December 1 2015March 31 2018
    Zika-Associated Birth Defects Reported in Pregnancies with Laboratory Evidence of Confirmed or Possible Zika Virus Infection — U.S. Zika Pregnancy and Infant Registry, December 1, 2015–March 31, 2018
    Roth, Nicole M. ;
    Reynolds, Megan R.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Zika Virus infection during pregnancy can cause serious birth defects of the brain and eyes, including intracranial calcifications, cerebral or cortical atrophy, chorioretinal abnormalities, and optic nerve abnormalities (1,2). The frequency of these Zika-associated brain and eye defects, based on data from the U.S. Zika Pregnancy and Infant Regist ...
    Supporting Files Public Domain
  • Morbidity and Mortality Weekly Report MMWR Surveillance Summaries January 2022 Vol 71 No SS2
    Morbidity and Mortality Weekly Report (MMWR): Surveillance Summaries, January 2022 / Vol. 71 / No. SS-2
    Phares, Christina R. ;
    Liu, Yecai
    01/21/2022 | Surveillance Summaries: Morbidity and Mortality Weekly Report (MMWR)
    Each year, approximately 500,000 immigrants and tens of thousands of refugees (range: 12,000–85,000 during 2001–2020) move to the U.S. While still abroad, immigrants, refugees, and others who apply for admission to live permanently in the U.S. must undergo a medical examination. This examination identifies persons with class A or B conditions. Appl ...
    Supporting Files Public Domain
  • Effectiveness of a Third Dose of mRNA Vaccines Against COVID19Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION Network 10 States August 2021January 2022
    Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
    Thompson, Mark G. ;
    Natarajan, Karthik
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination of these and other factors. CDC recommends that all persons aged ≥12 years receive a third dose (booster) of an mRNA vaccine ...
    Supporting Files Public Domain
  • QuickStats Percentage of Children Aged 217 Years with 2 Hours of Screen Time Per Weekday by Sex and Age Group National Health Interview Survey US 2020
    QuickStats: Percentage of Children Aged 2–17 Years with >2 Hours of Screen Time Per Weekday, by Sex and Age Group — National Health Interview Survey, U.S. 2020
    Ng, Amanda E. ;
    Black, Lindsey I.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Overall, 65.7% of boys and 64.6% of girls aged 2–17 years spent >2 hours of screen time per weekday, in addition to screen time spent for schoolwork. Among both boys and girls, the percentage of children who spent >2 hours of screen time increased with increasing age group from 47.5% for those aged 2–5 years to 80.2% for those aged 12–17 years.Sour ...
    Supporting Files Public Domain
  • Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged 19 Years Recommendations of the Advisory Committee on Immunization Practices US 2022
    Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — U.S. 2022
    Anderson, Tara C. ;
    Masters, Nina B.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit vaccine containing recombinant glycoprotein E in combination with adjuvant (AS01|) that was licensed in the U.S. for Prevention of herpes zoster for adults aged ≥50 years by the Food and Drug Administration (FDA) and recommended for immunocomp ...
    Supporting Files Public Domain
  • Use of the Janssen Johnson Johnson COVID19 Vaccine Updated Interim Recommendations from the Advisory Committee on Immunization Practices United States December 2021
    Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
    Oliver, Sara E. ;
    Wallace, Megan
    01/21/2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for its ...
    Supporting Files Public Domain
  • Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID19 US March 2020August 2021
    Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — U.S. March 2020–August 2021
    Wiltz, Jennifer L. ;
    Feehan, Amy K.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The COVID-19 pandemic has magnified longstanding health care and social inequities, resulting in disproportionately high COVID-19-associated illness and death among members of racial and ethnic minority groups (1). Equitable use of effective medications (2) could reduce disparities in these severe outcomes (3). Monoclonal antibody (mAb) therapies a ...
    Supporting Files Public Domain
  • Effectiveness of a Third Dose of MRNA Vaccines Against COVID19associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance VISION Network 10 States August 2021January 2022
    Effectiveness of a Third Dose of MRNA Vaccines Against COVID-19–associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance — VISION Network, 10 States, August 2021–January 2022
    Thompson, Mark G. ;
    Natarajan, Karthik
    January 21, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? COVID-19 mRNA vaccine effectiveness (VE) in preventing COVID-19 might decline because of waning of vaccine-induced immunity or Variants immune evasion.What is added by this report? VE was significantly higher among patients who received their second mRNA COVID-19 vaccine dose <180 days before medical encounters compared with those vaccinated ≥180 days earlier. During both Delta- and Omicron-predominant periods, receipt of a third vaccine dose was highly effective at preventing COVID-19–associated emergency department and urgent care encounters (94% and 82%, respectively) and preventing COVID-19–associated hospitalizations (94% and 90%, respectively).What are the implications for public health practice? All unvaccinated persons should start vaccination as soon as possible. All adults who have received mRNA vaccines during their primary COVID-19 vaccination series should receive a third dose when eligible, and eligible persons should stay up to date with COVID-19 vaccinations.Suggested citation for this article: Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. ePub: 21 January 2022.mm7104e3.htm?s_cid=mm7104e3_wmm7104e3-H.pdf
    Supporting Files Public Domain
981 - 1000 / 9550
 Was this page helpful?
 Found an issue?
Send us an email at: publishinghd@cdc.gov